PHIA Koninklijke Philips N.V.

Philips brings AI into the procedure room to assist doctors during heart valve repair

Philips brings AI into the procedure room to assist doctors during heart valve repair

 November 17, 2025



Innovation uses AI to track and visualize tiny repair devices* through the beating heart, helping clinicians navigate in 3D with enhanced clarity and confidence**



Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced DeviceGuide, an AI-powered device tracking* solution that assists physicians during one of interventional cardiology’s most technically demanding procedures: repairing leaking heart valves through a minimally invasive approach. Built on , this software brings AI directly into the procedure room, translating complex imaging into intuitive, real-time visual guidance that helps clinicians navigate the beating heart with greater clarity and confidence. It will be previewed at (November 16-18), one of the world’s leading meetings for structural heart specialists.



“With DeviceGuide, we’re bringing AI into the heart of the procedure room, and into the heart itself,” said Dr. Atul Gupta, Chief Medical Officer, Diagnosis & Treatment at Philips. “This is Philips’ first AI assisting physicians in real time to visualize and guide heart valve treatment devices* as they navigate the beating heart. It’s helping doctors in the moment as they are helping their patients with structural heart disease.”



Minimally invasive treatment of the mitral valve

A leaking heart valve, known as mitral valve regurgitation, is a condition in which blood leaks backward through the heart’s mitral valve. It affects more than 35 million [1] adults worldwide, leaving many short of breath, fatigued, and struggling with everyday activities like climbing stairs or walking short distances. Many also live with anxiety or fear, knowing their heart isn’t pumping efficiently. If left untreated, severe cases can lead to heart failure and other serious complications.



For patients who are too frail for open-heart surgery, minimally invasive transcatheter repair techniques such as mitral transcatheter edge-to-edge repair (M-TEER) offer a vital treatment option. During these procedures, physicians repair a leaking valve through a tiny incision in the top of the leg in the groin area, guiding long, flexible instruments through the blood veins and navigating a miniature repair device into the beating heart.



Clinicians must view and interpret both X-ray and ultrasound images on multiple screens, coordinate movements between two operators, and make precise adjustments to grasp the moving valve leaflets, position the repair device, and confirm the result in real time. The process demands accuracy, coordination, and experience from the team. This is where DeviceGuide can help with its 3D navigation support.



How AI is helping

DeviceGuide uses an AI algorithm to automatically track the tiny repair device as it moves through the beating heart, intelligently combining live echo and X-ray images. It creates a virtual 3D model of the treatment device in real time, superimposed on the live images of the beating heart. This allows clinicians to see where the device is and in which direction it is pointing, providing a clear view of the procedure and potentially enabling them to navigate the device more easily to effectively seal the leak.



“The AI software serves as an assistive tool, with the physician always remaining in control. This isn’t about replacing expertise – it’s about amplifying it,” added Dr. Atul Gupta. “By embedding AI into the procedure, DeviceGuide gives physicians an extra pair of eyes, effectively bionic vision, helping them treat more patients safely and confidently.”



Collaboration with Edwards Lifesciences

This innovation was developed in close collaboration with Edwards Lifesciences, the manufacturer of these repair devices. The solution combines Philips’ expertise in medical imaging and AI technologies with Edwards’ global leadership in structural heart innovation. Together, the companies have reimagined key parts of the mitral TEER procedural workflow.



“DeviceGuide demonstrates the impact of combining leading imaging and therapy expertise to develop solutions designed around the procedural workflow, a model that will shape the future of AI-enabled image-guided structural interventions,” said Mark Stoffels, Business Leader, Image Guided Therapy Systems.



This solution illustrates how Philips’ imaging and AI expertise can merge with the insights of leading therapy companies to innovate procedural workflows. This kind of collaboration is a model for developing the next generation of AI-enabled, image-guided innovations, centered on the needs of clinicians and their patients.



Read more on how Philips DeviceGuide works .

[1]



Philips DeviceGuide enabled by EchoNavigator R5 is not available for sale or use in all countries. Its availability is subject to local regulatory clearance and market release. Please contact your Philips representative for details on product availability in your region.




*DeviceGuide is currently intended for use only with the Mitral TEER Therapy Device (Edwards PASCAL Ace).





**DeviceGuide assists physicians in visualizing and navigating the repair device within the heart. It supports, but does not perform, the therapeutic procedure itself.

For further information, please contact:



Joost Maltha

Philips Global External Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.



Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments



EN
17/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new...

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member April 2, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the of the Medical Device Innovation Consortium (). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration () and other agency partners to help ensure patient access to medical device inn...

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch